CWF19L2

Across TCGA pan-cancer cohorts, CWF19L2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CWF19L2 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CWF19L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CWF19L2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where CWF19L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.714	0.368	.004	27	view →
UCEC	DFS	Median	All	0.842	0.964	.004	26	view →
PDAC	OS	Median	III,IV	0.456	0.218	.040	2	view →
HNSC	DFS	Median	III,IV	0.690	0.892	.017	2	view →
GBM	DFS	Quartile	All	0.674	0.884	.029	1	view →
LUAD	OS	Median	All	0.897	0.778	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CWF19L2–CCRCC (DFS)

Open the CCRCC breakdown →